The INeS study: prevention of multiple pregnancies: a randomised controlled trial comparing IUI COH versus IVF e SET versus MNC IVF in couples with unexplained or mild male subfertility. by Bensdorp, A.J. et al.
BioMed CentralBMC Women's Health
ssOpen AcceStudy protocol
The INeS study: prevention of multiple pregnancies: a randomised 
controlled trial comparing IUI COH versus IVF e SET versus MNC 
IVF in couples with unexplained or mild male subfertility
Alexandra J Bensdorp*, Els Slappendel, Carolien Koks, Jur Oosterhuis, 
Annemieke Hoek, Peter Hompes, Frank Broekmans, Harold Verhoeve, 
Jan Peter de Bruin, Janne Meije van Weert, Maaike Traas, Jacques Maas, 
Nicole Beckers, Sjoerd Repping, Ben W Mol, Fulco van der Veen and 
Madelon van Wely
Address: Department of Obstetrics and Gynaecology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
Email: Alexandra J Bensdorp* - a.j.bensdorp@amc.nl; Els Slappendel - els.slappendel@catharina-ziekenhuis.nl; 
Carolien Koks - c.koks@mmc.nl; Jur Oosterhuis - j.oosterhuis@ziekenhuis-mst.nl; Annemieke Hoek - a.hoek@og.umcg.nl; 
Peter Hompes - P.Hompes@vumc.nl; Frank Broekmans - F.Broekmans@umcutrecht.nl; Harold Verhoeve - H.R.Verhoeve@olvg.nl; Jan Peter de 
Bruin - j.d.bruin@jbz.nl; Janne Meije van Weert - j.m.van.rijn@mca.nl; Maaike Traas - M.traas@obgyn.umcn.nl; 
Jacques Maas - j.maas@mumc.nl; Nicole Beckers - n.beckers@erasmusmc.nl; Sjoerd Repping - s.repping@amc.uva.nl; 
Ben W Mol - b.w.mol@amc.uva.nl; Fulco van der Veen - f.vanderveen@amc.uva.nl; Madelon van Wely - m.vanwely@amc.uva.nl
* Corresponding author    
Abstract
Background: Multiple pregnancies are high risk pregnancies with higher chances of maternal and
neonatal mortality and morbidity. In the past decades the number of multiple pregnancies has
increased. This trend is partly due to the fact that women start family planning at an increased age,
but also due to the increased use of ART.
Couples with unexplained or mild male subfertility generally receive intrauterine insemination IUI
with controlled hormonal stimulation (IUI COH). The cumulative pregnancy rate is 40%, with a
10% multiple pregnancy rate.
This study aims to reveal whether alternative treatments such as IVF elective Single Embryo
Transfer (IVF e SET) or Modified Natural Cycle IVF (MNC IVF) can reduce the number of multiple
pregnancy rates, but uphold similar pregnancy rates as IUI COH in couples with mild male or
unexplained subfertility. Secondly, the aim is to perform a cost effective analyses and assess
treatment preference of these couples.
Methods/Design: We plan a multicentre randomised controlled clinical trial in the Netherlands
comparing six cycles of intra-uterine insemination with controlled ovarian hyperstimulation or six
cycles of Modified Natural Cycle (MNC) IVF or three cycles with IVF-elective Single Embryo
Transfer (eSET) plus cryo-cycles within a time frame of 12 months.
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BMC Women's Health 2009, 9:35 http://www.biomedcentral.com/1472-6874/9/35Couples with unexplained subfertility or mild male subfertility and a poor prognosis for treatment
independent pregnancy will be included. Women with anovulatory cycles, severe endometriosis,
double sided tubal pathology or serious endocrine illness will be excluded.
Our primary outcome is the birth of a healthy singleton. Secondary outcomes are multiple
pregnancy, treatment costs, and patient experiences in each treatment arm. The analysis will be
performed according tot the intention to treat principle. We will test for non-inferiority of the
three arms with respect to live birth. As we accept a 12.5% loss in pregnancy rate in one of the
two IVF arms to prevent multiple pregnancies, we need 200 couples per arm (600 couples in total).
Discussion: Determining the safest and most cost-effective treatment will ensure optimal chances
of pregnancy for subfertile couples with substantially diminished perinatal and maternal
complications. Should patients find the most cost-effective treatment acceptable or even
preferable, this could imply the need for a world wide shift in the primary treatment.
Trial registration: Current Controlled Trials ISRCTN 52843371
Background
Since the 1980s the percentage of multiple pregnancies in
the Netherlands has increased, as it has in most Western
European countries. The tendency of women to delay
starting a family until an advanced age with subsequent
higher chances of spontaneous multiple pregnancy, is a
major cause of this [1]. Also, the increase in assisted-
reproduction techniques such as intra-uterine insemina-
tion (IUI) and in-vitro fertilisation (IVF) has contributed
significantly tot the higher number of multiple pregnan-
cies [2]. Multiple pregnancy is the most frequent and
most serious iatrogenic complication of assisted repro-
ductive technologies [3,4].
Women carrying multiple pregnancies have an increased
risk of numerous ante- and postpartum complications,
such as pregnancy-related diabetes and pre-eclampsia
(12%). The chief risk for the infant is preterm birth with
an incidence approaching 43%. Prematurely delivered
children are prone to suffer from respiratory distress syn-
drome, bronchopulmonary dysplasia, intraventricular
bleeding and pneumonia. Furthermore, the prevalence of
growth retardation (42 to 57%) is much higher within
children delivered from multiple pregnancies. Altogether,
these tribulations lead to high morbidity and a mortality
rate of about 3% [5,6]. Admission costs to the neonatal
intensive care unit are high and result in a two to four fold
increased cost per child born. Additionally, the long-term
costs due to handicaps like spastic cerebral palsy are sub-
stantial, and subsequently a burden for society.
Both opinion leaders and members of the European and
American Societies for Reproductive Medicine (ESHRE
and ASRM) consider multiple pregnancies following ART
unacceptable for patients and society at large. The presi-
dents of the ESHRE and ASRM have urged their members
to prioritize research to prevent multiple pregnancies fol-
lowing assisted reproductive techniques.
Of subfertile couples no less than 50% are diagnosed
with unexplained infertility or mild male subfertility, and
particularly at risk for multiple pregnancy. In approxi-
mately half of these couples the prognosis to conceive
spontaneously is unfavourable. In this study we define an
unfavourable prognosis as chances of spontaneous con-
ception below 30% in the next 12 months according to
the model of Hunault [7]. In couples with a favourable or
intermediate prognosis of treatment independent preg-
nancy, it has been established that expectant manage-
ment during six months is most opportune [8,9].
However, in couples with an unfavourable diagnosis
there is ambiguity about the preferred first line treatment.
At present, the recommended fertility treatment in these
patients is intra-uterine insemination (IUI) with control-
led ovarian hyperstimulation (COH) over six cycles
(guideline NVOG). Evidence to support this was estab-
lished in two systematic reviews where IUI in the natural
cycle was less effective than IUI with COH [10,11]. A
recent randomised controlled trial found that there was
no significant difference in live birth rate, whether stimu-
lation was performed using clomiphene citrate (CC) or
gonadotropins [12].
IUI with either form of controlled ovarian stimulation
results in considerable pregnancy rates 12.7% (Anderson
2008) at the expense of a large number of multiple preg-
nancies. National registries in the Netherlands show that
multiple pregnancy rate after IUI with or without COH is
about 10% [13]. The multiple pregnancy rate after IVF
Double Embryo Transfer (DET) is about 25%, and results
generated from European registers by ESHRE show mul-
tiple delivery rates for IVF are still around 23%. To eradi-
cate this unacceptable consequence of the current ART-
practice, every effort has to be put into preventing multi-
ple pregnancies following assisted reproductive tech-
niques.Page 2 of 8
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gies have been developed. Firstly, the modified natural
cycle IVF (MNC-IVF) was evaluated by the research group
from the University Medical Center Groningen. The
cumulative clinical pregnancy rate was 37% after six
cycles. Live birth rate was 32% per patient. There were 4
multiple pregnancies [14]). Currently MNC is offered as
a first line treatment to IVF patients in their clinic.
Also, IVF with elective single embryo transfer (eSET) has
been evaluated as a policy to prevent multiple pregnan-
cies. Cumulative pregnancy rates after the embryo trans-
fer of one good quality embryo have been described to be
over a 30% [15-17] whereas the multiple pregnancy rates
have been low, around 2-3%.
It is clear that multiple pregnancies can largely be pre-
vented by with MNC-IVF and IVF-eSET. However, preven-
tion of multiple pregnancies will only be opportune
when high delivery rates can be maintained. Presently,
the main problem is that evidence to conclude which one
of these treatments is most effective, and cost efficient, is
lacking. Also, up to this date, there has been no large ran-
domised controlled trial investigating patient preference
comparing these different treatments types. If alternative
treatment types are safer and preferable from a patient
point of view, this could lead to a shift in standard prac-
tice in this population.
Objective
To study whether MNC IVF and IVF COH can prevent
multiple pregnancies, and are effective alternatives to IUI
COH in terms of a healthy singleton, multiple pregnan-
cies, costs and patient preferences.
Methods
Participating centres
This study is a multicentre randomised controlled trial in
IVF centres and their affiliated clinics in The Netherlands.
Inclusion started in January 2009.
Inclusion criteria
Couples with female age between 18 and 38 years, diag-
nosed with unexplained or mild male subfertility, failure
to conceive within at least 12 months of unprotected
intercourse, and poor prognosis, are eligible. In this
study, a poor prognosis is defined as a chance of sponta-
neous pregnancy below 30% within 12 months as calcu-
lated by the validated model of Hunault [18,19], or
failure to conceive within at least 3 years of unprotected
intercourse. Mild male subfertility is defined as pre-wash
total motile sperm count above 10 million or a post-wash
total motile sperm count above 1 million.
Patients with polycystic ovary syndrome or any other
anovulation, double-sided tubal pathology, endocrin-
opathological disease (Cushing syndrome, adrenal
hyperplasia, hyperprolactinemia, acromegaly, imminent
ovarian failure, premature ovarian failure, hypothalamic
amenorrhea, diabetes mellitus (type I) will not be
included.
Ethical considerations
Approval for this study was obtained from the Medical
Ethical Committee of the Academic Medical Centre and
from the Central Committee on Research involving
Human Subjects (CCMO), The Netherlands. In patients
fulfilling the inclusion criteria, written informed consent
is obtained before randomisation is carried out. Women
refusing participation are registered.
Randomisation
Randomisation is performed by accessing a central inter-
net-based randomisation program and is stratified for
hospital.
Interventions
Couples are allocated to a treatment strategy consisting of
6 consecutive cycles of IUI-COH or 6 cycles of MNC-IVF
or 3 cycles of IVF-eSET plus subsequent cryo-cycles. Cou-
ples are treated until pregnancy occurs within a treatment
time horizon of 12 months. (Figure 1).
Prior to start of IUI-COH patients will undergo Chlamy-
dia antibody testing, hysterosalpingography and/or
laparoscopy to exclude double sided tubal occlusion.
In IUI-COH the controlled ovarian hyperstimulation can
be performed with 100 mg clomiphene citrate or by daily
subcutaneous injections of 75 IU FSH starting from cycle
day three or four onward. The follicular growth is strictly
monitored by transvaginal ultrasound. When at least one
follicle with a diameter of 17 or 18 mm is present, final
oocyte maturation is induced by the administration of
5.000 IU human chorionic gonadotropin (hCG) (Preg-
nyl, Organon, Oss, The Netherlands), and 36 hours there-
after IUI will be performed. HCG administration and IUI
will be withheld when monitoring reveals the growth of
more than three follicles with a diameter of 16 mm, or
more than five follicles with a diameter of 12 mm. Semen
samples are processed within one hour after ejaculation,
using a density gradient centrifugation followed by wash-
ing with culture medium and is subsequently used for
insemination.
In MNC-IVF the oocyte that develops spontaneously is
used for IVF. The cycle is minimally modified with a
GnRH antagonist to prevent untimely ovulations,
together with FSH to prevent collapse of the follicle and aPage 3 of 8
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Flowchart of studyigure 1
Flowchart of study.
 Inclusion INeS Study:
 • Age 18-38 yrs
 • Unexplained subfertility 
 • Mild male subfertility 
• TMSC pre wash 10 x 106 
• TMSC post wash 1 x 106  
• Poor prognosis 
• <30% spontaneous pregnacy (Hunault)  
Informed Consent
Randomisation
No
 Exclusion INeS study:
 • Anovulation or PCOS
 • Severe endometriosis
 • Endocrinopathological disease 
• Double sided tubal pathology
Birth of a healthy singleton
• Follow up until 6 weeks after birth 
Secondary Outcomes
 • Multiple pregnancies 
 • Pregnancy Complications (pre-term birth, dysmaturity, PIH, PE, HELLP) 
• Costs
 • Patient preference
Log 
registration
IUI COH 
• 6 cycles
• Treatment time 12 months
MNC IVF
• 6 cycles 
• Treatment time 12 months 
  IVF e SET
• 3 fresh cycles + cryo-cyles
• Treatment time 12 months
  PCOS polycystic ovarian syndrome
  IUI COH intra uterine insemination + controlled  ovarian hyperstimulation
  MNC IVF Modified natural cycle IVF 
IVF e SET elective single embryo IVF 
  PIH pregnancy induced hypertension 
  PE pre eclampsia 
  HELLP syndrome (hypertension, elevated liver enzymes, low platelet count
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ing will be started on cycle day 8 or 10 and repeated daily
or every other day, according to the size of the lead folli-
cle. Follicle diameter will be measured in three perpen-
dicular planes, and the mean value will be taken. When a
lead follicle with a mean diameter of at least 14 mm is
observed, daily injections of 0.25 mg of a GnRH-antago-
nist together with 150 IU FSH are started. GnRH-antago-
nist will be continued up to and including the day of
ovulation triggering. FSH will be continued up to the day
of ovulation triggering. Patients will be instructed to have
their injections at the same time daily, to ensure a 24
hour interval between injections. Ovulation triggering
will be achieved by subcutaneous injection of 10 000 IU
of hCG (Pregnyl®, Organon, Oss, the Netherlands) when
a follicle with a diameter of 17 to 18 mm is observed.
Blood samples will be taken for assessment of serum con-
centrations of LH and E2 on the days that ultrasound was
performed. Cycles where an LH-rise of > 30.0 IU/L is
noticed at a follicle size of < 15 mm will be cancelled. In
cases where an LH-rise of > 30.0 IU/L is noticed, HCG is
given and follicle aspiration will be performed the next
day. There will be no flushing of the follicle. Only large
(dominant) follicles will be aspirated. Embryo transfer
will be performed on the second or third day after oocyte
retrieval. Usually one oocyte is obtained, and one embryo
is placed in utero. Should there be more than one good
quality embryo, the surplus embryos will be cryo pre-
served.
For luteal support, HCG 1500 IU (Pregnyl®, Organon,
Oss, the Netherlands) will be given five, eight and eleven
days after oocyte retrieval.
For IVF-eSET women will undergo controlled ovarian
hyperstimulation after down-regulation with a GnRH
agonist in a long protocol with a midluteal start or with a
fixed start antagonist protocol starting on day two. Con-
trolled ovarian hyperstimulation is started with 150 IU
FSH. Treatment is continued until at least 2 follicles > 18
mm have developed. Ovulation is induced by 10.000 IU
human chorionic gonadotropin hormone (hCG) (Preg-
nyl®, Organon, Oss, The Netherlands) and cumulus-
oocyte complexes will be recovered by transvaginal ultra-
sound-guided retrieval 36 hours thereafter. Embryos will
be scored with the use of validated morphological scoring
criteria at the time of fertilization (pronuclear morphol-
ogy) and daily until the time of transfer. Embryos will be
assessed for their morphology daily by an embryologist/
IVF-technician using an Olympus IX71 inverted micro-
scope or another equivalent microscope equipped with
Relief Contrast optics at a magnification of 320 x. On day
two, three or four, one embryo will be selected for trans-
fer if one or more embryos of good quality are available.
If no good quality embryos are available two embryos
will be transferred. Non-transferred good quality
embryos will be cryo-preserved. Embryo scoring will be
done according to the participating laboratories' own
protocol. When implantation is not successful or early
miscarriage occurs the frozen embryos are thawed and
transferred. Again, only one embryo will be transferred
per frozen-thaw cycle if it is of good quality.
Before starting a new treatment cycle with IUI-COH,
MNC-IVF or IVF-eSET, women will undergo a pregnancy
test (hCG measurement in serum or urine). If no preg-
nancy has manifested the next treatment cycle is started
according to protocol. In case of a positive pregnancy test
women will be monitored using ultrasound visualisation
during their pregnancy. Monitoring will take place at five
to nine weeks of amenorrhea to check whether an intrau-
terine gestational sac is present, i.e. a clinical pregnancy.
Subsequently monitoring will take place at 11 to 12
weeks amenorrhea to register the presence of an intrauter-
ine gestational sac with foetal heart beat, i.e. an ongoing
pregnancy.
Follow up
Short term follow up
As the primary outcome is birth of a healthy child result-
ing from a pregnancy that was established in the first 12
months after randomization, each child will be assessed
at 6 weeks after the expected day of delivery. For example,
a child that is born at a gestational age of 38 weeks will be
assessed at 8 weeks after birth, whereas a child born after
a gestational age of 30 weeks will be assessed 16 weeks
after birth. Parents will be contacted by telephone to
enquire on the delivery and the health of the child. When
necessary, child health centres and or paediatricians will
then be contacted for specific information. All children
with severe morbidity will be evaluated and classified by
a panel of neonatologists. Detailed information on
maternal complication will be obtained from the obste-
trician treating the woman concerned.
Certainly not all couples will complete the 12 months of
treatment. Drop-outs will largely represent normal
patient flow. We aim to keep track of all drop-outs and to
document the reason for the drop-out in the database.
Long term follow up
We will not be able to follow the children during their
lives within the context of this study. However, the health
status and subsequent development of children born
after IVF and ICSI seems to be comparable to those after
spontaneous conception up to the age of 5 years [20].
Furthermore it was recently shown that couples in whom
eSET was applied, did not have an unfavourable outcomePage 5 of 8
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singletons [21].
Outcome measures
Primary outcome measure
The primary outcome is the birth of a healthy singleton.
A child will be considered healthy when born at term
with a normal birth weight, without congenital anoma-
lies [22] and with a normal paediatric examination and
development assessment at 6 weeks of age.
Secondary outcome measures
Naturally, multiple pregnancy, defined as registered
heartbeat of at least two foetuses at 12 weeks of gestation
is a secondary outcome. A multiple birth in which al least
one of the children has congenital anomalies, will con-
sidered as failure of the strategy.
Further secondary outcomes are clinical pregnancy,
defined as any registered embryonic heartbeat at sonogra-
phy; neonatal mortality; pregnancy complications (pre-
term birth < 37 weeks, birth weight < 2.500 gram,
Pregnancy Induced Hypertension (PIH), (pre-) eclamp-
sia, HELLP) costs and patients' preferences.
Patients' preferences are assessed by an (online) ques-
tionnaire using a discrete choice experiment (DCE) based
on characteristics of both interventions and will be com-
pared with a control group, recruited among women vis-
iting the infertility clinics of the participating hospitals.
Background and Demographic Characteristics
To assess whether the treatment groups were balanced,
the study populations will be compared for baseline
measurements including female age, type of infertility
(primary/secondary), duration of infertility, intoxica-
tions, body mass index, as well as sperm analysis accord-
ing to WHO standards.
Analysis
The analysis of all outcomes is on an intention to treat
basis. The analysis will be a cost-minimisation when the
effectiveness is comparable in all groups. In case of differ-
ences in effectiveness a cost-effectiveness study will be
performed. Couples will be treated within a time horizon
of 12 months
Differences in birth rate per group will be expressed as rel-
ative risks with corresponding 95% confidence intervals.
A formal test of the difference in pregnancy rate will be
performed using chi-square test statistics. Birth rates over
time will be compared using life tables.
The medical, economical and social dilemma concerns
children with handicaps, which are mostly due to pre-
term birth. A literature search will therefore be performed
to estimate live-long costs due to handicaps. We will sub-
sequently perform a scenario analysis, in which we will
model the costs and effects of the three strategies in this
perspective.
Economic Evaluation
We plan an economic evaluation alongside the clinical
trial. A distinction will be made between costs of medical
interventions (direct costs) and costs resulting from pro-
ductivity losses (indirect or time costs). Standardised unit
costs will be calculated for all centres based on actual
expenses made during the study. Subsequently, unit costs
will be applied to resource use as observed in the partici-
pating centres. Resource utilisation will be documented
using individual patient data in the case record forms. In
addition, each woman will receive questionnaires at 4
weeks, 8 weeks, 12 weeks, 24 weeks, 36 weeks and 48
weeks after treatment start for details on associated direct
costs of professional care, and on indirect costs like trans-
portation and productivity loss. Resource unit prices will
reflect the unit of staff, materials, equipment, housing,
depreciation, and overhead. Productivity loss will be val-
ued using Dutch reference data (handbook of the Dutch
health Council). Costs will be presented in Euros.
As the neonatal morbidity and mortality is likely to
depend on the number of multiple births, we will per-
form sensitivity analyses in which we will vary the
number of multiple pregnancies in the IUI-COH strategy.
Furthermore, sensitivity analyses will be performed on
costs, pregnancy rates of the different treatment strategies
and the valuation of different outcomes (no child, hand-
icapped child, healthy child).
Power calculation
Considering an expected birth rate of a healthy child after
12 months of treatment of 40% in all three treatment
groups, with an alpha of 5% and a beta of 20%, 190
patients per group are required to exclude a difference of
12.5% or more to the detriment of MNC-IVF and IVF-
eSET. To account for an estimated early drop-out of 5%
we will include 200 patients per group.
Discussion
Each year about 5000 couples in the Netherlands are
diagnosed with unexplained or mild male and an unfa-
vourable prognosis [23]. As stated earlier, in these cou-
ples there is ambiguity about the preferred first line
treatment.
The incidence of multiple pregnancies with the standard
treatment is substantial. This has far reaching conse-
quences regarding maternal and neonatal morbidity, but
also with regard to societal costs. Therefore alternativePage 6 of 8
(page number not for citation purposes)
BMC Women's Health 2009, 9:35 http://www.biomedcentral.com/1472-6874/9/35treatments need to be considered. To this date no large
randomised controlled trials which have compared IUI
COH with IVF e SET, and MNC IVF in couples with unex-
plained or mild male subfertility in order to prevent mul-
tiple pregnancies.
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